Neurosense Therapeutics (NRSN) Reports Positive Biomarker Data from ALS Phase 2b Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
August 1, 2024 9:15 AM EDT12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation
Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy
CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ --Â NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a... More
